BRAF and non-small cell lung carcinoma: Consistent with these findings, the further study confirmed that NSCLC patients with BRAF mutations displayed similar sensitivity to ICI-based monotherapy or combined therapies compared with those with WT BRAF. To the best of our knowledge, our work is the first report on the immunophenotype in BRAF mutated NSCLC.